Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020
June 23 2020 - 8:00AM
Molecular diagnostics company Genetic Technologies Limited (ASX:
GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its
interim-CEO Dr. George Muchnicki will share insight into the
Company’s recent developments during an investor webinar, hosted by
RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A
live Q&A session with Dr. Muchnicki will follow the
presentation.
To register for the free webinar, please visit:
https://www.redchip.com/corporate/webinar_register/63
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a
diversified molecular diagnostics company. GTG offers cancer
predictive testing and assessment tools to help physicians
proactively manage patient health. The Company’s lead products
GeneType for Breast Cancer for non-hereditary breast cancer and
GeneType for Colorectal Cancer are clinically validated risk
assessment tests and are first in class.
Genetic Technologies has capacity for COVID-19 testing and is
developing a pipeline of risk assessment products.
For more information, please visit www.gtglabs.com.
Contact: Dave Gentry, CEO RedChip
Companies Office: 1 800 RED CHIP (733 2447) Cell: US 407 491 4498
dave@redchip.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024